These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 32788235)

  • 1. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA.
    Barata P; Agarwal N; Nussenzveig R; Gerendash B; Jaeger E; Hatton W; Ledet E; Lewis B; Layton J; Babiker H; Bryce A; Garje R; Stein C; Kiedrowski L; Saylor P; Sartor O
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32788235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA;
    N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
    Abida W; Cheng ML; Armenia J; Middha S; Autio KA; Vargas HA; Rathkopf D; Morris MJ; Danila DC; Slovin SF; Carbone E; Barnett ES; Hullings M; Hechtman JF; Zehir A; Shia J; Jonsson P; Stadler ZK; Srinivasan P; Laudone VP; Reuter V; Wolchok JD; Socci ND; Taylor BS; Berger MF; Kantoff PW; Sawyers CL; Schultz N; Solit DB; Gopalan A; Scher HI
    JAMA Oncol; 2019 Apr; 5(4):471-478. PubMed ID: 30589920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of Next-generation Sequencing of Liquid Biopsy (Circulating Tumor DNA) Samples and Tumor Tissue from Patients with Metastatic Prostate Cancer in a Real-world Clinical Setting in Germany.
    Mandel P; Hoeh B; Humke C; Doering C; Wenzel M; Cano Garcia C; Fuhr N; Koll F; Fassl A; Tilki D; Steuber T; Faull I; Jeroch J; Ebner S; Schmitt C; Reis H; Köllermann J; Kokkaliaris KD; Demes MC; Chun FKH; Wild PJ
    Eur Urol Focus; 2024 Mar; 10(2):339-345. PubMed ID: 38493067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer.
    Chakrabarti S; Bucheit L; Starr JS; Innis-Shelton R; Shergill A; Dada H; Resta R; Wagner S; Fei N; Kasi PM
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35710297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies.
    Graham LS; Montgomery B; Cheng HH; Yu EY; Nelson PS; Pritchard C; Erickson S; Alva A; Schweizer MT
    PLoS One; 2020; 15(5):e0233260. PubMed ID: 32453797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.
    Graff JN; Beer TM; Alumkal JJ; Slottke RE; Redmond WL; Thomas GV; Thompson RF; Wood MA; Koguchi Y; Chen Y; Latour E; Bergan RC; Drake CG; Moran AE
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32616555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.
    O'Malley DM; Bariani GM; Cassier PA; Marabelle A; Hansen AR; De Jesus Acosta A; Miller WH; Safra T; Italiano A; Mileshkin L; Xu L; Jin F; Norwood K; Maio M
    J Clin Oncol; 2022 Mar; 40(7):752-761. PubMed ID: 34990208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
    Marabelle A; Le DT; Ascierto PA; Di Giacomo AM; De Jesus-Acosta A; Delord JP; Geva R; Gottfried M; Penel N; Hansen AR; Piha-Paul SA; Doi T; Gao B; Chung HC; Lopez-Martin J; Bang YJ; Frommer RS; Shah M; Ghori R; Joe AK; Pruitt SK; Diaz LA
    J Clin Oncol; 2020 Jan; 38(1):1-10. PubMed ID: 31682550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.
    Tucker MD; Zhu J; Marin D; Gupta RT; Gupta S; Berry WR; Ramalingam S; Zhang T; Harrison M; Wu Y; Healy P; Lisi S; George DJ; Armstrong AJ
    Cancer Med; 2019 Aug; 8(10):4644-4655. PubMed ID: 31270961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
    Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
    EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade.
    Georgiadis A; Durham JN; Keefer LA; Bartlett BR; Zielonka M; Murphy D; White JR; Lu S; Verner EL; Ruan F; Riley D; Anders RA; Gedvilaite E; Angiuoli S; Jones S; Velculescu VE; Le DT; Diaz LA; Sausen M
    Clin Cancer Res; 2019 Dec; 25(23):7024-7034. PubMed ID: 31506389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel.
    Willis J; Lefterova MI; Artyomenko A; Kasi PM; Nakamura Y; Mody K; Catenacci DVT; Fakih M; Barbacioru C; Zhao J; Sikora M; Fairclough SR; Lee H; Kim KM; Kim ST; Kim J; Gavino D; Benavides M; Peled N; Nguyen T; Cusnir M; Eskander RN; Azzi G; Yoshino T; Banks KC; Raymond VM; Lanman RB; Chudova DI; Talasaz A; Kopetz S; Lee J; Odegaard JI
    Clin Cancer Res; 2019 Dec; 25(23):7035-7045. PubMed ID: 31383735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis.
    Mosalem O; Tan W; Bryce AH; Dronca RS; Childs DS; Pagliaro LC; Orme JJ; Kase AM
    Prostate Cancer Prostatic Dis; 2024 Feb; ():. PubMed ID: 38341460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.
    Le DT; Kim TW; Van Cutsem E; Geva R; Jäger D; Hara H; Burge M; O'Neil B; Kavan P; Yoshino T; Guimbaud R; Taniguchi H; Elez E; Al-Batran SE; Boland PM; Crocenzi T; Atreya CE; Cui Y; Dai T; Marinello P; Diaz LA; André T
    J Clin Oncol; 2020 Jan; 38(1):11-19. PubMed ID: 31725351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Experience of Pembrolizumab Administration in A Patient with Castration-Resistant Microsatellite Instability-High Prostate Cancer].
    Takasawa T; Amano T; Himeno M; Imao T
    Hinyokika Kiyo; 2024 Feb; 70(2):51-54. PubMed ID: 38447945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing.
    Al Zoughbi W; Fox J; Beg S; Papp E; Hissong E; Ohara K; Keefer L; Sigouros M; Kane T; Bockelman D; Nichol D; Patchell E; Bareja R; Karandikar A; Alnajar H; Cerqueira G; Guthrie VB; Verner E; Manohar J; Greco N; Wilkes D; Tagawa S; Malbari MS; Holcomb K; Eng KW; Shah M; Altorki NK; Sboner A; Nanus D; Faltas B; Sternberg CN; Simmons J; Houvras Y; Molina AM; Angiuoli S; Elemento O; Mosquera JM
    Oncologist; 2021 Nov; 26(11):e1971-e1981. PubMed ID: 34286887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
    Roncati L
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations.
    Park JJ; Chu A; Li J; Ali A; McKay RR; Hwang C; Labriola MK; Jang A; Kilari D; Mo G; Ravindranathan D; Graham LS; Sokolova A; Tripathi A; Pilling A; Jindal T; Ravindra A; Cackowski FC; Sweeney PL; Thapa B; Amery TS; Heath EI; Garje R; Zakharia Y; Koshkin VS; Bilen MA; Schweizer MT; Barata PC; Dorff TB; Cieslik M; Alva AS; Armstrong AJ
    JCO Precis Oncol; 2024 Apr; 8():e2300567. PubMed ID: 38579192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.